ToGA study showed that for HER-2-positive gastric cancer patients, trastuzumab combined with chemotherapy resulted in the longest overall survival and enhanced efficacy for intestinal gastric cancer, with the worst prognosis being for diffuse gastric cancer patients. Here, ERBB2 is linked to gastric cancer.